Latest news with #RIS
Time of India
2 days ago
- Business
- Time of India
Nagaland varsity signs pact with RIS for research collab
Dimapur: Nagaland University signed an MoU with Research and Information System for Developing Countries (RIS), an autonomous think tank under the ministry of external affairs, becoming one of the 23 Indian universities to sign the agreement, reports Bhadra Gogoi. The University Connect Hub, established under this MoU, aims to facilitate collaborative research, knowledge sharing, and capacity building between NU and RIS. The MoU was signed on the sidelines of the international conference on 'Global South and Triangular Cooperation: Emerging Facets' held on June 3 and June 4, a varsity release said on Thursday. Prof Sachin Chaturvedi, DG, RIS, and Prof Jayanta Choudhury head of the department of rural development and planning, NU, signed the MoU on behalf of their institutions. The University Connect Hub will do joint research and resource pooling, organise seminars on global economy, climate change, and development finance, hold faculty exchange programmes, conduct joint publications and research dissemination and exchange of research publications.
Indian Express
4 days ago
- Business
- Indian Express
ICRISAT launches agri co-op centre for Global South
The International Crops Research Institute for Semi-Arid Tropics (ICRISAT) and Research and Information System for Developing Countries (RIS) launched Tuesday a new Centre of Excellence for transformation of agriculture in developing countries through South-South cooperation. The new Centre— ICRISAT Centre of Excellence for South-South Cooperation in Agriculture (ISSCA) — based in Hyderabad, will serve as a catalyst for translating agricultural solutions into scalable impact. At a press meet, RIS Director General Sachin Chaturvedi said this Centre will take India's development experience to other developing nations. It would democratise agricultural knowledge and translate experience into policy. Sharing an example of collaboration between countries, Chaturvedi said Ethiopia and Kenya have approached the RIS, seeking support for institutional framework to have growth of the private seed industry in their countries.
New Indian Express
26-05-2025
- Business
- New Indian Express
Who will replace Chaturvedi in RIS?
After a two-year pause, Nalanda University finally has a full-time vice-chancellor. Economist Sachin Chaturvedi has taken charge, succeeding Sunaina Singh, who served a notably extended six-year term. As he steps into his new academic role, Chaturvedi has also been asked to continue as Director General of the Research and Information System for Developing Countries (RIS), a New Delhi-based government think tank. RIS, supported by a Governing Council that includes the ministries of external affairs, economic affairs, finance, science and technology, and commerce, is a multi-country platform that advises developing nations on regional and global economic issues. With Chaturvedi juggling both hats, the Ministry of External Affairs has begun looking for a full-time replacement at RIS. The brief? A candidate with at least 15 years of experience in research and teaching in economics or a related field—including five years as a professor. Unsurprisingly, this has piqued the interest of many former bureaucrats and policy veterans keen to throw their hats into the ring. Traditionally, the RIS has maintained a balance of scholarly and diplomatic heft: its president is a former Indian Foreign Service officer, while the DG is typically an economist—a mix that keeps the numbers and the nuance in check. 'Go far and wide with Op Sindoor' BJP MPs, senior leaders, and other NDA allies are understood to have been asked to promote the success of Operation Sindoor as widely as possible through their social media platforms, including X. 'Every detail which showcases the abilities of our armed forces must be amplified globally and within the country to make their bravery public,' remarked a BJP functionary. He added that Union cabinet ministers have also been mobilised to popularise government achievements under Prime Minister Modi and highlight the success of Operation Sindoor's success. A source remarked that the suggestion appears to have spurred a competition of sorts, with 'everyone in the cabinet and in organisational roles engaged in a global digital race to ensure Modi's reach extends across the world.'
Yahoo
19-05-2025
- Business
- Yahoo
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT-621 Phase 1 healthy volunteer SAD/MAD trial completed with data to be reported in June 2025 KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) ongoing with data expected in 4Q25 Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively WATERTOWN, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the presentation of additional preclinical data for KT-621, its potent, selective, oral STAT6 degrader and the first STAT6 targeted medicine to enter clinical development. The new asthma efficacy mouse model data showed both prevention of disease progression as well as reversal of established disease, building upon the compelling preclinical characterization of KT-621 as a potential once daily, oral treatment for asthma and other Th2 allergic and atopic diseases. These data were presented at the American Thoracic Society (ATS) International Conference being held May 16-21, 2025, in San Francisco, CA. Additionally, Jared Gollob, MD, Kymera's Chief Medical Officer, was featured in an oral showcase presentation as part of the ATS Respiratory Innovation Summit (RIS) discussing the Company's industry-leading oral immunology portfolio, including the KT-621 program. 'We believe KT-621 represents an enormous opportunity to expand patient access to an oral systemic advanced therapy in many common immuno-inflammatory diseases, such as asthma, that have limited or suboptimal treatment options,' said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. 'KT-621's impressive and consistent preclinical data package shows the revolutionary potential of STAT6 degradation to phenocopy the activity of upstream biologics, like dupilumab, while offering the convenience of a once daily oral medicine. These encouraging results in an established and clinically validated asthma mouse model with both a prophylactic and now therapeutic treatment regimen further increase our confidence in the transformative potential of KT-621 as we approach our Phase 2b trial in asthma early next year. We look forward to sharing updates from our KT-621 Phase 1 trials in healthy volunteers next month and atopic dermatitis patients later this year.' The Company previously demonstrated that KT-621 prevents disease progression in the prophylactic intranasal house dust mite (HDM)-induced model in IL-4/IL-4RA humanized mice. KT-621 robustly inhibited all the tested cytokines, chemokines, cell infiltrates, and lung remodeling involved in Th2 inflammation in asthma to an extent comparable or superior to an IL-4Rα saturating dose of the injectable IL-4Rα antibody, dupilumab, included in the same study. New data shared at ATS show that in the HDM-induced chronic mouse model with a therapeutic treatment regimen, KT-621 administered orally after disease establishment demonstrated comparable or superior activity to dupilumab in blocking Th2 inflammation. The Company also shared new histology data from the therapeutic efficacy model showing amelioration of lung remodeling, including goblet cell metaplasia and MUC5AC mRNA expression, after low daily oral doses of KT-621 that was superior to dupilumab. Overall, the preclinical data shared to date demonstrate the best-in-pathway potential of KT-621 for the treatment of Th2 allergic and atopic diseases given its dupilumab-like activity profile and the convenience of an oral pill. The Company has completed the Phase 1 healthy volunteer trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending (SAD/MAD) doses of KT-621 compared to placebo. In June 2025, Kymera will host a webcast to disclose the complete KT-621 Phase 1 healthy volunteer SAD/MAD data, which will include STAT6 degradation, safety and additional biomarker results. Additionally, the KT-621 BroADen Phase 1b trial in moderate to severe AD patients is ongoing, with data expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b trials in AD and asthma are planned to start in 4Q25 and 1Q26, respectively. Copies of both the ATS and RIS presentations are available in the Resource Library section of Kymera's website. About KT-621KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation. STAT6 degradation has the potential to provide the convenience of an oral medicine with the potential for biologics-like activity and in doing so reach broader patient populations compared to injectable biologics or other standards of care. In preclinical studies, KT-621 demonstrated dupilumab-like activity in several in vitro and in vivo models and was safe and well tolerated. KT-621, the first STAT6 directed medicine to enter clinical evaluation, has the opportunity to transform treatment paradigms for more than 130 million patients around the world, including children and adults, suffering from Th2 diseases such as AD, asthma, chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), chronic spontaneous urticaria (CSU), and prurigo nodularis (PN), among others. About Kymera TherapeuticsKymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston's top workplaces for the past several years. For more information about our science, pipeline and people, please visit or follow us on X or LinkedIn. Availability of Other Information About Kymera TherapeuticsFor more information, please visit the Kymera website at or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and the progress, timing and objectives on the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the advancement in Phase 1 clinical testing. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target," "upcoming" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future trials and the results of such trials, whether preclinical results will be indicative of the results of clinical trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with regulatory authorities, the availability of funding sufficient for our operating expenses and capital expenditure requirements and other factors. These risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Investor and Media Contact: Justine KoenigsbergVice President, Investor Relationsinvestors@ 857-285-5300Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Perth Now
19-05-2025
- Automotive
- Perth Now
EV, hybrid servicing and repairs set to cost more, take longer under new laws
New regulations for technicians working on electric vehicles (EVs) and hybrids in New South Wales could cause delays and see service costs rise due to a shortage of technicians meeting the new qualifications. The proposed rules would require mechanics to complete additional battery tech and safety courses before they can legally work on EVs and hybrids. The regulations have been proposed as part of a new Act to replace the current Motor Dealers and Repairers Regulation which expires on September 1, 2025. Should these pass into law, the rules will be applied to new mechanics and the 49,000 existing mechanics in NSW – which make up one third of the total number across Australia – even those having already worked on EVs. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. Supplied Credit: CarExpert The regulations extend to technicians carrying out 'steering, suspension and wheel alignment work' meaning tyre fitters may also be required to take the course in order to legally perform a wheel alignment on an EV. The Australian Automotive Aftermarket Association (AAAA) estimates only around 10 per cent of technicians in NSW have completed any EV training. The AAAA also argues it's more challenging for technicians in regional areas to access the training and take the time out of their workshop to complete it. The regulations have been proposed by New South Wales (NSW) Fair Trading, which provides the regulatory framework for the buying, selling and repair of motor vehicles across the state. There are around 7.4 million cars on NSW roads, according to Fair Trading's data. Supplied Credit: CarExpert The official course is the AURSS00064 Battery Electric Vehicle Inspection and Servicing Skill Set. It costs between $1500–$3000 and takes six days to complete, with some education providers advertising it over a four-day period. It's not just EV servicing and repair work affected, with hybrids – which also feature a high-voltage battery – also impacted. The proposed laws state that a tradesperson with certificates in three repair classes, such as electrical accessory fitting work, radiator repair work, and steering, suspension, and wheel alignment work, will also be prohibited from working on hybrid vehicles until they complete a mandatory course, dubbed Depowering and reinitialising BEVs – AURETH101 Depower and reinitialise battery. Supplied Credit: CarExpert According to the AAAA the regulations, revealed in a Regulatory Impact Statement (RIS), are 'deeply flawed' and need to be reviewed. 'This is not just a workforce issue — it's a consumer issue,' AAAA chief executive officer Stuart Charity in a statement. 'This rushed approach will reduce access to essential repair services and increase costs for NSW motorists.' Mr Charity suggests the 'rushed approach' included a lack of consultation with industry groups such as the AAAA, which recommends 'transition plans' for EV training in NSW. 'We agree that technicians working on high-voltage vehicles must be trained and competent — and that's already happening,' Mr Charity added. 'But this proposal creates a legislative barrier that will drastically reduce the number of qualified service providers overnight. It will drive up costs for consumers and cause serious delays in repair and servicing.'
